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after Alternative-Donor Hematopoietic
Stem Cell Transplantation
Stefania Coppoletta, Elisabetta Tedone, Barbara Galano, Monica Soracco,
Anna Maria Raiola, Teresa Lamparelli, Francesca Gualandi, Stefania Bregante,
Adalberto Ibatici, Carmen di Grazia, Alida Dominietto, Riccardo Varaldo, Barbara Bruno,
Francesco Frassoni, MariaTeresa Van Lint, Andrea BacigalupoWe report 55 patients undergoing an alternative-donor hematopoietic stem cell transplantation (HSCT)
who developed Epstein-Barr virus (EBV) DNAemia, with.1000 EBV copies/105 peripheral blood mononu-
clear cells (PBMCs), and were treated with rituximab (375 mg/m2). The median patient age was 47 years
(range, 20-65 years), and graft sources were mismatched family members (n 5 4), unrelated donors (n 5
46), and unrelated cord blood (n 5 5). The conditioning regimen included antithymocyte globulin (ATG)
in all patients. The median time to development of EBV DNAemia was day 27 post-HSCT (range, day 5 to
day 242), with a median of 60 EBV copies/105 PBMCs (range, 1-5770 copies/105 PBMCs). The number of
EBV copies was reduced to\1000/105 PBMCs on day 17 after initiation of rituximab therapy in 51% of
the patients, on day114 in 73% of the patients, and on121 in 92% of the patients. Overall, 50 of 55 patients
(91%) cleared EBV after one dose (n5 25) or more than one dose (n5 25) of rituximab. Factors predicting
transplantation-related mortality (TRM) in multivariate analysis were a reduction to\1000 EBV copies/105
PBMCs by day 17 of treatment (relative risk [RR], 0.2; P 5 .01) and disease phase in remission (RR, 0.3;
P 5 .05). TRM was 23% in the 40 patients with none or one of the negative predictors and 60% in the 15
patients with both negative predictors (P5 .001). Of these latter 15 patients, 3 developed clinical posttrans-
plantation lymphoproliferative disorder (PTLD). All 3 of these patients had a high EBV load on day 17 of
rituximab therapy. This study confirms the effectiveness of rituximab in controlling EBVDNAemia in patients
undergoing allogeneic HSCT. Patients with increasing EBV copies despite rituximab therapy are at high risk
for EBV PTLD and may be considered for alternative therapies.
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Epstein-Barr virus (EBV) DNAemia is a frequent
event after hematopoietic stem cell transplantation
(HSCT) from an alternative donor when T cell deple-
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6/j.bbmt.2010.10.003used [1]. A significant proportion of patients with
EBV DNAemia are at risk of developing posttrans-
plantation lymphoproliferative disease (PTLD), which
can be life-threatening [2], especially in the presence of
a high viral load [3]. The prevalence of EBV after allo-
geneic HSCT may be underestimated; a review of 77
autopsies identified 19 cases of PTLD (25%), only 7
of which had been diagnosed while the patient was
alive [4].
Risk factors for PTLD identified in a significant
number of more than 20,000 HSCTs studied were ex
vivo TCD, in vivo TCD with ATG given as graft-
versus-host disease (GVHD) prophylaxis or treatment,
development of acute or chronic GVHD, older age at
transplantation (.50 years), and a second allogeneic
HSCT [5].
Until the 1980s, there was no effective therapy for
PTLD, and most patients died with uncontrolled901
Table 1. Clinical Data for 55 Patients Receiving Rituximab for
EBV Reactivation
Number of patients 55
Recipient sex, M/F, n 28/27
Recipient age, years, median (range) 47 (20-65)
Donor sex, M/F, n 38/17
Donor age, years, median (range) 38 (3-54)
Interval from diagnsosis to HSCT, days,
median (range)
445 (180-7158)
Phase of disease CR1/>CR1, n 17/38
Median year of HSCT (range) 2005 (2002-2008)
Donor type: mismatched rekated/unrelated/
umbilical cord blood, n
4/46/5
Median day of EBV reactivation (range) 27 (5-242)
Median EBV copies at reactivation, n (range) 60 (1-5170)
Median EBV copies at rituximab treatment, n (range) 2578 (1089-54,106)
Median maximum EBV copies, n (range) 6354 (1104-71,000)
EBV copies are expressed as copies/105 PBMCs.
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apy is, of course, one possible strategy, although a re-
cent trial found only one response in 16 patients [7].
Treatment of PTLD with donor-derived T cells was
shown to be effective 20 years ago [8], and long-term
follow-up ofmore than 100 patients patients confirmed
a long-lasting positive effect [9]. With the increasing
clinical use of monoclonal antibodies, rituximab has
become a readily available alternative therapy for
EBV PTLD and has been used successfully in recipi-
ents of transplants fromhaploidentical or unrelated do-
nors. The number of patients treated with rituximab in
these studies ranged between 3 and 9 inHSCTs andbe-
tween 6 and 43 in solid organ transplantations, with re-
ported success rates of 40%-100% [10-18]. Overall,
treatment was well tolerated, and the success rate was
significant; nevertheless, several concerns were raised
in a recent review [9], including the fact that rituximab
does not restore immunity to EBV and targets only one
antigen, allowing for selection of tumor cell variants. In
otherwords, waiting until the development of clinically
evident PTLD with rapidly enlarging lymph nodes
may lead to failure in a significant proportion of pa-
tients, unless allogeneic EBV cytotoxic T lymphocytes
(CTLs) are available [9].
One alternative option is to treat EBV preemp-
tively, when viral copies exceed a threshold associated
with PTLD. We previously showed that patients with
.1000 EBV copies/105 peripheral bloodmononuclear
cells (PBMCs) are at high risk for developing lethal
PTLD [19]. In that study of 77 patients, PTLD oc-
curred in no patients with 0 EBV copies/105 PBMCs,
in 2.5% of patients with \1000 EBV copies/105
PBMCs, and in 33% of patients with$1000 EBV cop-
ies/105 PBMCs. We have since switched to the use of
rituximab for all patients with $1000 EBV copies/105
PBMCs, and have retrospectively evaluated 55 consec-
utive HSCT patients treated accordingly.PATIENTS AND METHODS
Patients
Patients who underwent HSCT in our unit at San
Martino Hospital, Genova, between 2002 and 2008
were analyzed retrospectively for the purpose of this
study. All patients received rabbit ATG 7.5-10 mg/
kg (Genzyme, Boston, MA) in the conditioning regi-
men. The standard dose was 7.5 mg/kg, given in two
divided doses of 3.75 mg/kg. A group of 18 patients
was randomized to receive two additional doses of
1.25 mg/kg on days 17 and 19 (total dose, 10 mg/
kg) [20]. Donor and recipient characteristics are sum-
marized in Table 1. Patient care was provided in accor-
dance with our standard transplantation protocols,
including a conventional conditioning regimen for
most patients, based on cyclophosphamide and totalbody irradiation [21], or reduced-intensity condition-
ing based on the combination of thiotepa and cyclo-
phosphamide [22]. Nine patients received rituximab
200 mg as single-dose prophylaxis on day 15 post-
transplantation.EBV Load Monitoring
Patients were monitored by polymerase chain re-
action (PCR) weekly starting on day115 and continu-
ing to day 1100, and then at successive outpatient
examinations for up to 1 year posttransplantation. Pe-
ripheral blood samples were collected on EDTA, and
DNA was extracted using the QIAamp DNA blood
kit (Qiagen, Hilden, Germany), then eluted in 110
mL of buffer solution. The highly purified DNA was
amplified using the EBVRGPCRKit (Qiagen), which
includes EBV-specific primers encoding for the
EBNA1 gene, Deoxynucleoside triphosphate (dNTPs),
the amplification buffer, Hot Start TAQ polymerase
Qiagen, Valencia, CA USA, and a fluorogenic probe.
The reaction was performed in a Rotor Gene 3000
(Corbett Research, Bath UK) with a program consist-
ing of one cycle of 95C for 10minutes, followed by 45
cycles of 95C for 15 seconds, 55C for 30 seconds, and
72C for 20 seconds. The EBV RG PCR Kit and pu-
rified water was used as a negative control. Viral load
was expressed as number of EBV DNA copies/105
PBMCs.Treatment of EBV DNAemia
Patients with $1000 EBV copies/105 PBMCs had
cyclosporin therapy discontinued in the absence of
GVHD and were started on rituximab 375 mg/m2, ad-
ministered as a slow 8-hour infusion. Patients who did
not clear EBV from peripheral blood by 7 days after
the initiation of rituximab therapy received a second
dose of rituximab 375 mg/m2. Patients with $1000
EBV copies/105 PBMCs on day 14 received a third
dose and, 1 week later, a fourth dose of rituximab.
Figure 1. Median number of EBV copies/105 PBMCs at different time
intervals after the initial dose of rituximab therapy.
Figure 2. Percentage of patients with .1000 EBV copies/105 PBMCs:
100% on day 0 of rituximab therapy, 53% on day 17, 27% on day 114,
8% on day 121, and 2% on day 128.
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Disease
The diasgnosis of PTLD was based on the pres-
ence of the following criteria: increasing EBV DNA
load, systemic symptoms, and a computed tomography
scan showing rapidly progressive disseminated nodal
disease.
Statistical Analysis
Patients data were analyzed with theNCSS statisti-
cal softtwarepackage (NCSS,Kaysville,UT).Compar-
isons were performed using the c2 test for categorical
variables and the nonparametric Mann-Whitney U
test for continuous variables. Transplantation-related
mortality (TRM) is expressed as cumulative incidence.
Actuarial survival was calculated using the Kaplan-
Meier method. A multivariate Cox analysis was run
with TRM or overall survival as the endpoint, using
patient and transplantation variables.RESULTS
Treatment with Rituximab
All 55 patients received one dose of rituximab, 25
patients received two doses, and 4 patients received
more than two doses. The median number of EBV
DNA copies is depicted in Figure 1. The viral load in-
creased from a median of 176 copies/105 PBMCs to
a median of 2578 copies/105 PBMCs in 1 week, and
then declined after initiation of rituximab therapy
(Figure 1). All patients had .1000 EBV copies/105
PBMCs on day 0; the proportion of patients with
.1000 copies was 29/55 patients (53%) on day 17,Table 2. Hemtologic Values on Days 0, +7, +14, and +21 of Rituxim
Day 0 Da
Hemoglobin, g/dL 9 (7.3-14) 9 (7.
WBC 109/L 4.6 (0.4.14) 4.5 (0.
ANC 109/L 3.8 (0.4-10.6) 3.1 (0.
Lymphocytes 109/L 0.5 (0.1-4.6) 0.7 (0.
Platelets 109/L 78 (6-286) 77 (6-
†Significant difference (P <.01) compared with day 0 values.14/52 (27%) on day114, 4/52 (8%) on day121, 1/50
(2%) on day 128, and 0 thereafter (Figure 2).Side Effects and Peripheral Blood Counts after
Rituximab Therapy
Tolerance of rituximab infusion was generally
good, given the conventional premedication and slow
infusion over a period of many hours. Median
hemoglobin and white blood cell and platelet counts
before the initiation of rituximab therapy and on
days 17, 114, and 121 after initiation are presented
in Table 2. Other than a significant decline in neutro-
phil count on days114 and121, there were no signif-
icant differences in these paremeters over time.Transplantation-Related Mortality
The overall cumulative incidence of TRM was
33%. In univariate analysis, factors predicting TRM
at P#.10 were number of EBV copies on day17, dis-
ease phase, patient age, timing of EBVDNAemia (me-
dian, day127 post-HSCT), and maximum number of
EBV copies (median, 6354/105 PBMCs) (Table 3). In
particular, patients who reduced their EBV load to
\1000 copies  105 PBMCs on day 17 (n 5 27) after
the first dose of rituximab had significantly lower
TRM compared with those with $1000 EBV copies/
105 PBMCs on day 17 after initiation of rituximab
therapy (21% vs 44%; P5 .03), and patients in remis-
sion (complete response [CR] 1 and CR2) had lower
TRM compared with those in disease phase beyond
CR2 (26% vs 37%; P 5 .10).ab Treatment
y +7 Day +14 Day +21
2-12.3) 10 (7.4-11.3) 10 (5.9-12.3)
5-21) 3.5 (0.4-13.9) 3.4 (0.4-17)
2-14.8) 2.4 (0.6-9.1)† 1.7 (0.3-8.5)†
1-6.5) 0.9 (0.1-5.6) 0.7 (0.1-6.9)
330) 67 (7-814) 69 (9-700)
Table 3. Univariate and Multivariate Cox Analysis of Factors Predicting TRM
Univariate Multivariate
% TRM P RR P
Patient age </$ 45 years 26% vs 39% .10 0.39 .18
Donor age </$ 38 years 32% vs 33% .90
Donor sex, M/F 29% vs 41% .30
Recipient sex, M/F 35% vs 29% .60
Disease phase, CR1 + CR2/advanced 26% vs 37% .10 0.32 .05
EBV reactivation day 27, >/# 22% vs 41% .10 0.43 .12
EBV load at time of rituximab treatment, </$ 2578 copies 32% vs 33% .80
EBV copies on day +7, </$ 1000 21% vs 44% .03 0.21 .01
Maximum EBV copies 6354, </$ 25% vs 40% .10 1.00 .90
ATG dose 7.5 vs 10 mg/kg 30% vs 39% .80
EBV copies are expressed as copies/105 PBMCs.
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a multivariate analysis (Table 3). The number of EBV
copies on day 17 and disease phase remained signifi-
cant predictors. Figure 3 compares TRM in patients
with zero or one of these two negative predictors
(n5 40; 23%) and those with both negative predictors
(n 5 15; 60%) (P 5 .001) who did not reduce their
EBV load to \1000 copies/105 PBMCs by day 17
and had advanced disease.Overall Survival
The overall actuarial survival rate at 5 years was
32%. The same predictors of TRM, also predicted
overall survival: a reduction in the number of EBV
copies to\1000/105 PBMCs by day 17 (relative risk
[RR], 0.28; P 5 .004) and disease phase (RR, 0.36;
P 5 .01). There was a borderline effect of age \45
years (RR, 0.45; P5 .04). Figure 4 outlines the overall
survival of the same two groups of patients stratified
according to prognostic factors for TRM. The figure
shows a 40% 5-year survival for patients who reducedFigure 3. Cumulative incidence of TRM in patients stratified according
to two negative predictors: failure to reduce EBV copies to\1000/105
PBMCs on day17 of rituximab therapy and disease phase beyond CR2.
TRM is 23% in patients with none or one of these negative predictors
and 60% in those with both negative predictors (P 5 .001).their EBV copies to\1000/105 PBMCs and/or had
early-phase disease (CR1 or CR2) at the time of trans-
plantation versus 13% for patients with both negative
predictors (P 5 .002).
Responders on Day 17
Table 4 outlines the two groups of patients, those
with\1000 EBV copies/105 PBMCs on day 17 and
those with $1000 copies. The group of responders
(n 5 28) demonstrated a trend toward delayed EBV
DNAemia. Although the median interval from trans-
plantation to initiation of rituximab therapy was the
same in the two groups (27 days), themean interval dif-
fered (27 days in the former group vs 44 days in the lat-
ter). The responders also had a lower maximum
number of EBV copies (3582 vs 19,143/105 PBMCs;
P5 .00001). A small number of patients received a sec-
ond dose of rituximab despite having\1000 EBV cop-
ies/105 PBMCs on day17 after initiation of rituximab
therapy, as ordered by the attending physician. Due toFigure 4. Actuarial survival in patients stratified according to two neg-
ative predictors: failure to reduce EBV copies\1000/105 PBMCs on day
17 of rituximab therapy and disease phase beyond CR2. Survival is 40%
in patients with none or one of these negative predictors and 13% in
those with both negative predictors (P 5 .002).
Table 4. Clinical Data for Patients, Stratified According to Rituximab Response on Day +7
Patients with <1000 EBV Copies/105
PBMCs on Day +7
Patients with <1000 EBV Copies/105
PBMCs on Day +7 P Value
Number of patients 28 27
Recipient sex, M/F, n 12/16 16/11 .20
Donor sex, M/F, n 20/8 18/9 .90
Donor age, years, median (range) 33 (0-54) 38 (0-52) .80
Recipient age, years, median (range) 50 (20-75) 41 (23-63) .07
Diagnosed/treated, n, median (range) 577 (10-7158) 360 (355-5125) .50
Disease phase CR1 + CR2, % 60% 55% .60
Year of HSCT, median (range) 2005 (2003-2008) 2005 (2002-2008) .10
Graft source: mismatched related/unrelated/cord blood, n 1/25/2 3/21/3 .20
Conditioning regimen, myeloablative vs reduced intensity, n 13/15 15/12 .40
Median day of EBV reactivation (range) 27 (5-242) 27 (12-52) .09
Median EBV copies at reactivation, n (range) 41 (1-1452) 60 (1-5570) .10
Median EBV copies at rituximab treatment, n (range) 2031 (1089-32,898) 6575 (2421-10,729) .40
Median maximum EBV copies, n (range) 2241 (1104-4618) 11996 (2870-71,000) .00004
Rituximab >1 dose, n. of pts. 20/6 3/26 .00001
TRM, % 21% 44% .04
Cleared EBV, n (%) 28 (100%) 22 (81%) .01
Death before day +14, n 0/26 3/29 .10
Death before day +28, n 0/26 5/29 .03
EBV copies are expressed as copies/105 PBMCs.
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despite having .1000 EBV copies/105 PBMCs on
day 17. All responders (100%) cleared EBV com-
pletely by day 17, compared with 81% of nonre-
sponders (P 5 .01) (Table 4).
The response on day 17 after initiation of rituxi-
mab therapy was greater in patients with fewer than
the median number of EBV copies on day 0 (64% vs
36%; P 5 .06). The median maximum number of
EBV copies was 6341/105 PBMCs. Response on day
17 was 100% in the 28 patients who did not exceed
this number of EBV copies and 81% in the 27 patients
who did exceed this level (P5 .01). Early death, before
day114 or day128, occurred only in patients who did
not reduce their number of EBV copies to\1000/105
PBMCs by day 117.Failure to Clear Rituximab
Five patients failed to clear EBV from the blood.
All 5 of these patients died, 3 from EBV PTLD and 2
from infection. In the former 3 patients, EBV PTLD
was diagnosed based on rising levels of EBVDNAemia
despite rituximab therapy, along with a positive com-
puted tomography scan for mediastinal and/abdominalTable 5. Causes of Death, Stratified According to Rituximab
Response on Day +7
Patients with <1000
EBV Copies/105
PBMCs on Day +7
Patients with $1000
EBV Copies/105
PBMCs on Day +7
Number of patients 28 27
Alive, n 13 9
Acute GVHD, n 0 1
Chronic GVHD, n 0 1
Infections, n 6 7
EBV PTLD, n 0 3
Leukemia, n 9 6nodes and systemic symptoms. One of these patients
underwent transplantation because of advanced Hodg-
kin disease.
Causes of Death
A total of 15 patients (27%) died due to relapsed
leukemia and 18 (33%) died from a transplantation-
related complication. Table 5 presents causes of death
according to response on day17 after initiation of rit-
uximab treatment. There was a trend toward increased
deaths due to GVHD, infections, and PTLD in the
nonresponders. In the 5 patients who did not clear
EBV, acute GVHD was scored as absent (n 5 2) or
grade I (n 5 3); the primary cause of death was EBV
PTLD in 3 of these patients and other infections in
the other 2 patients.DISCUSSION
In this study, we have shown that rituximab is an
effective preemptive therapy for EBV DNAemia,
with a 91% response. Approximately half of our pa-
tients required more than one dose of rituximab to
clear the virus, and response to rituximab by day 17
after the initiation of therapy is the major predictor
of CR, TRM, and survival.
As to the first observation, we elected to treat our
patients on the basis of a given level of EBV copies/
105 PBMCs based on our previous finding of a 50%
risk of developing PTLD when the number of EBV
copies exceeds 1000/105 PBMCs [19]. We are aware
of groups who used different cutoff levels of EBV, as
well as different ways of expressing EBV copies (ie,
per mL of blood rather than per 105 PBMCs [23-25]),
and standardization of monitoring procedures clearly
would be desirable. In the present study, we describe
906 Biol Blood Marrow Transplant 17:901-907, 2011S. Coppoletta et al.patients monitored using a homogenous quantitative
PCR method, with EBV copies referred to a given
number (105) of PBMCs. At a median interval of 27
days posttransplantation, 55 patients had .1000 EBV
copies/105 PBMCs and were treated with rituximab at
the standard dose of 375 mg/m2. With conventional
premedication, given as a slow infusion over several
hours, rituximab was well tolerated overall, and the
full dose could be given to all patients. With the
exception of neutrophil counts, peripheral blood
counts did not decline significantly on days 17, 114,
and 121 after initiation of rituximab therapy. The
overall TRM for the study group was 32%, despite
a large proportion (69%) of patients with advanced
disease; this compares favorably with our previous
experience of 40% TRM, when patients with .1000
EBV copies/105 PBMCs were given rituximab only
after the development of PTLD. Treatment of ENB
DNA-emia has been grade feasible with an evidence
BII in a recent guideline paper [26].
The large majority of patients (50/55; 91%) cleared
EBV completely after rituximab therapy. This high suc-
cess rate compares favorably with other published series
of patients in whom rituximab therapy was instituted
later in the course of the disease, after clinical symptoms
of PTLD had already developed [17], with reported
success rates ranging from 40% to 100% [27].We won-
dered whether there was something special about our 5
patients who failed to clear EBV. All 5 patients reacti-
vated early, within 1 month posttransplantation, 4
within the median interval of 27 days; all 5 had a maxi-
mumnumber of EBV copies exceeding themedian level
(6354 copies/105 PBMCs), all 5 failed to reduce their
EBV load to\1000 copies/105 PBMCs by day17 after
the first dose of rituximab; 3 developed clinical overt
PTLD; and all 5 died within 114 days posttransplanta-
tion. This suggests that patients most likely to fail ritux-
imab therapy are those with early EBV DNAemia with
a high copy load and who do not clear the virus within 7
days from the first dose of rituximab; these patients are
at increased risk of PTLDand death. Some studies eval-
uating ‘‘prompt’’ versus ‘‘preemptive’’ treatment of EBV
DNAemia might have had this choice due to the avail-
ability of EBV-specific CTLs in the event of failure of
rituximab therapy. In the study of Wagner et al. [24],
patients were monitored for EBV load weekly by PCR
and were followed clinically when the load exceeded
4000 copies/mg of PBMC DNA. Only 8 patients who
developed clinical symptoms of EBV PTLD were
treated with rituximab (n 5 5) or EBV-specific CTLs
(n5 3). All 8 patients cleared EBV. Other investigators
have opted for the preemptive approach, such as a re-
cently published series of 19 patients who received rit-
uximab therapy based on EBV viral load (.40,000
copies/mL of blood) [25]. All patients cleared EBV,
and only one patient developed nonlethal PTLD. The
preemptive approach seems to be effective, althoughonly a randomized study of early versus later treatment
(at the time of symptoms) can determine whether this
approach is beneficial, or whether waiting for clinical
signs of PTLD to develop is more appropriate.
The secondmajor finding of this study is that a sin-
gle dose of rituximab was not sufficient to clear EBV in
approximately 50% of patients, as evaluated on day17
after the first dose. Our policy was to give a second
dose of rituximab to patients who did not reduce their
EBV load to below the threshold of 1000 copies/105
PBMCs. With this approach, 25 patients received
only one dose of rituximab, 25 received two doses,
and 4 received more than two doses. Overall, TRM
was higher in the patients who required more than
one dose of rituximab: 28% for patients receiving
one dose, 32% for those receiving two doses, and
75% for those receiving more than two doses. These
findings suggest that clearance of EBV is a strong pre-
dictor of outcome.
We then stratified patients according to the num-
ber of copies of EBV on day 17 after the first dose
of rituximab into two groups, with a cutoff value of
1000 copies/105 PBMCs. We found no differences
clinical pretransplantation data (age, sex, disease
phase, interval between diagnosis and HSCT, condi-
tioning regimen, stem cell source) between the pa-
tients who reduced their EBV viral load to \1000
copies/105 PBMCs by day 17 and those who did
not. We did find significantly higher TRM in the pa-
tients who failed to reduce their EBV viral load (21%
vs 44%; P 5 .03). The other variable predicting
TRM in multivariate analysis was disease phase (early
vs advanced). TRM was 60% in the 15 patients with
advanced disease (beyond CR2) who failed to reduce
their EBV load to \1000 copies/105 PBMCs, com-
pared with 23% in the 40 patients with none or only
one of these two negative predictors. The actuarial
survival following rituximab treatment was also influ-
enced by these two variables, with a significant
5-year survival advantage in the patients with none
or only one negative predictor (40% vs 13%).
In conclusion, preemptive rituximab therapy for
EBV DNAemia in patients undergoing alternative-
donor HSCT is well tolerated and associated with
a 91% EBV clearence rate. The speed of EBV clear-
ance and the disease phase at the time of transplanta-
tion are strong predictors of TRM. Patients
exhibiting a slow response on day 17 after initiation
of rituximab therapy may be considered for further rit-
uximab therapy or for other treatments, such as the
infusion of EBV-specific CTLs.ACKNOWLEDGMENTS
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